SEC Form 4 · accession 0001562180-18-001911
Sienna Biopharmaceuticals, Inc. · SNNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John W Smither
Officer — Chief Financial Officer
Period of report
Apr 16, 2018
Accepted (ET)
Apr 18, 2018 · 6:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001656328
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $19.59 | Apr 16, 2018 | A | 170,000 | A | — | Apr 16, 2028 | Common Stock | 170,000 | 170,000 | D |
Explanation of responses
- F1The underlying shares subject to the option will vest as follows: i) 20,000 shares subject to the option vest and become exercisable upon satisfaction of a performance-based milestone and ii) 150,000 shares subject to the option vest and become exercisable with respect to 25% of 150,000 shares on the first anniversary measured from April 16, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.